CA3195410A1 - Therapeutic radiolabelled conjugates and their use in therapy - Google Patents
Therapeutic radiolabelled conjugates and their use in therapyInfo
- Publication number
- CA3195410A1 CA3195410A1 CA3195410A CA3195410A CA3195410A1 CA 3195410 A1 CA3195410 A1 CA 3195410A1 CA 3195410 A CA3195410 A CA 3195410A CA 3195410 A CA3195410 A CA 3195410A CA 3195410 A1 CA3195410 A1 CA 3195410A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- nodaga
- therapeutic
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020903727 | 2020-10-14 | ||
| AU2020903727A AU2020903727A0 (en) | 2020-10-14 | Conjugates and their use in therapy | |
| PCT/AU2021/051203 WO2022077068A1 (en) | 2020-10-14 | 2021-10-14 | Therapeutic radiolabelled conjugates and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3195410A1 true CA3195410A1 (en) | 2022-04-21 |
Family
ID=81207378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3195410A Pending CA3195410A1 (en) | 2020-10-14 | 2021-10-14 | Therapeutic radiolabelled conjugates and their use in therapy |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230398240A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4228710A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7890301B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230130610A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116472068A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021359638A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3195410A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL302033A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004327A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022077068A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220152229A1 (en) | 2019-04-12 | 2022-05-19 | Centenary Institute Of Cancer Medicine And Cell Biology | Conjugates and their use as imaging agents |
| US20250269072A1 (en) * | 2021-10-14 | 2025-08-28 | Centenary Institute Of Cancer Medicine And Cell Biology | Processes for preparing radiolabelled conjugates |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100418585C (zh) * | 2003-07-24 | 2008-09-17 | 伯拉考成像股份公司 | 稳定的放射性药物组合物及制备方法 |
| WO2016088116A1 (en) * | 2014-12-05 | 2016-06-09 | University Health Network | Use of antioxidants as radio-protective agents |
| LT3275883T (lt) | 2015-03-25 | 2021-08-25 | Fujifilm Corporation | Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba |
| US20160367620A1 (en) * | 2015-06-19 | 2016-12-22 | Harry B. Demopoulos | Glutathione |
| US20220152229A1 (en) * | 2019-04-12 | 2022-05-19 | Centenary Institute Of Cancer Medicine And Cell Biology | Conjugates and their use as imaging agents |
-
2021
- 2021-10-14 CA CA3195410A patent/CA3195410A1/en active Pending
- 2021-10-14 KR KR1020237015744A patent/KR20230130610A/ko active Pending
- 2021-10-14 CN CN202180075143.7A patent/CN116472068A/zh active Pending
- 2021-10-14 JP JP2023547721A patent/JP7890301B2/ja active Active
- 2021-10-14 WO PCT/AU2021/051203 patent/WO2022077068A1/en not_active Ceased
- 2021-10-14 IL IL302033A patent/IL302033A/en unknown
- 2021-10-14 AU AU2021359638A patent/AU2021359638A1/en active Pending
- 2021-10-14 EP EP21878793.5A patent/EP4228710A4/en active Pending
- 2021-10-14 MX MX2023004327A patent/MX2023004327A/es unknown
-
2023
- 2023-04-12 US US18/299,304 patent/US20230398240A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116472068A (zh) | 2023-07-21 |
| JP7890301B2 (ja) | 2026-07-14 |
| IL302033A (en) | 2023-06-01 |
| KR20230130610A (ko) | 2023-09-12 |
| US20230398240A1 (en) | 2023-12-14 |
| MX2023004327A (es) | 2023-08-30 |
| EP4228710A4 (en) | 2025-04-09 |
| EP4228710A1 (en) | 2023-08-23 |
| WO2022077068A1 (en) | 2022-04-21 |
| JP2023547954A (ja) | 2023-11-14 |
| AU2021359638A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3498308B1 (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| ES2736134T3 (es) | Derivado peptídico de tiourea, compuesto marcado con radioisótopos que contiene el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para tratar o diagnosticar el cáncer de próstata | |
| EP3856261A1 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers | |
| US12296030B2 (en) | Conjugates and their use as imaging agents | |
| AU2019345320B2 (en) | Methods of treating cancer | |
| AU2009200201A1 (en) | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging | |
| US20230398240A1 (en) | Therapeutic radiolabelled conjugates and their use in therapy | |
| JP2023523226A (ja) | Psma結合リガンドを放射標識するための方法及びそのキット | |
| JP2022549258A (ja) | セラノスティックスとして使用するための放射性標識grprアンタゴニスト | |
| US20250269072A1 (en) | Processes for preparing radiolabelled conjugates | |
| CN120344273A (zh) | 二聚体放射性药物、其组合物及其用途 | |
| JP2024539952A (ja) | 放射性核種錯体の組み合わせ療法 | |
| HK40008701A (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide | |
| HK40008701B (en) | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240925 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240925 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240925 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250922 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250922 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251010 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251010 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251010 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251212 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20251212 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251212 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |